Last reviewed · How we verify
Allergovac depot — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Allergovac depot (Allergovac depot) — Roxall Medicina España S.A. Allergen immunotherapy that gradually desensitizes the immune system through repeated exposure to specific allergens in a depot formulation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Allergovac depot TARGET | Allergovac depot | Roxall Medicina España S.A | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Allergovac depot CI watch — RSS
- Allergovac depot CI watch — Atom
- Allergovac depot CI watch — JSON
- Allergovac depot alone — RSS
Cite this brief
Drug Landscape (2026). Allergovac depot — Competitive Intelligence Brief. https://druglandscape.com/ci/allergovac-depot. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing